Astria Therapeutics News and Activities
Presence
Astria Therapeutics develops medicines for allergic and immunologic diseases. Its main services include research and clinical development of antibody therapies for patients with rare conditions and for healthcare providers.
Astria Therapeutics products and services overview:
- Rare disease therapies
- Antibody treatments
- Clinical development
- Drug research
Revenue: ~$0 million
Employees: 95
Headquarters: Boston, United States (USA)
Biocryst Pharmaceuticals is one of the...
Biocryst Pharmaceuticals is a company listed under the stock ticker BCRX (US).
They are in:
- Biotechnology50%
- Pharmaceuticals50%
Acquisition, funding and merger involving Biocryst Pharmaceuticals.
- Biocryst Pharmaceuticals has announced the acquisition of Astria Therapeutics (posted on October 20 2025).
Executives
View the org chart displaying its 9 main executives
Most searched biographies at Astria Therapeutics
- Jessica Best, Vice President, Medical Affairs
- Paul Stanley, Vice President, Head of Quality
- Rafif Dagher, Senior Vice President and Head of Discovery, Nonclin...
Popular executive movements at Biocryst Pharmaceuticals
- Sandeep Menon has joined the company as Chief Research and Development Officer (posted on April 6 2026).
- Ron Dullinger, who was Senior Vice President, General Manager, Americas, is promoted to Chief Commercial Officer (posted on January 2 2026).
Create your alert
to follow the executive moves at Astria Therapeutics.
Pharmaceuticals
Biocryst Pharmaceuticals has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).
Popular M&A news in Pharmaceuticals
- Laboratoire Servier has announced the acquisition of Edgewise Therapeutics (posted on June 4 2026).
- Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
- Hims & Hers has acquired Eucalyptus (posted on June 2 2026).
Popular contacts in Pharmaceuticals
News
Press releases by Astria Therapeutics
- BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting | BioCryst Pharmaceuticals, Inc.
- BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026 | BioCryst Pharmaceuticals, Inc.
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BioCryst Pharmaceuticals, Inc.
- BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema | BioCryst Pharmaceuticals, Inc.
- BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update | BioCryst Pharmaceuticals, Inc.
- BioCryst to Present at Upcoming Investor Conferences | BioCryst Pharmaceuticals, Inc.
- BioCryst to Report First Quarter 2026 Financial Results on May 6 | BioCryst Pharmaceuticals, Inc.
- BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer | BioCryst Pharmaceuticals, Inc.
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BioCryst Pharmaceuticals, Inc.
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BioCryst Pharmaceuticals, Inc.
- View more press releases Close
Social media about Astria Therapeutics
- Astria Therapeutics on Wikipedia, Google News & Yahoo Finance
- Astria Therapeutics on LinkedIn, X (Twitter) & YouTube
